Neuro-ophthalmic sarcoidosis

Current Opinion in Ophthalmology

Volumn 21, Issue 6, 2010, Pages 423-429

  Phillips, Yanny L ^a   Eggenberger, Eric R ^a  

^a East Lansing   (United States)

Author keywords

neuro ophthalmology; optic neuropathy; sarcoidosis

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CHLORAMBUCIL; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA ANTIGEN; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIGENICITY; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DNA POLYMORPHISM; EPIDEMIOLOGICAL DATA; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GLUCOSE INTOLERANCE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; NEUROOPHTHALMIC SARCOIDOSIS; OBESITY; OPTIC NERVE DISEASE; OSTEOPOROSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REMISSION; REVIEW; SARCOIDOSIS; STEROID THERAPY; SYMPTOMATOLOGY;

HUMANS; OPTIC NERVE DISEASES; SARCOIDOSIS;

EID: 78049255374     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32833eae4d     Document Type: Review

References (103)

1. Hosada Y, Sasagawa S, Yasuda N. Epidemiology of sarcoidosis: new frontiers to explore. Curr Opin Pulm Med 2002; 8:424-428.
2. Frohman LP, Grigorian R, Bielory L. Neuro-ophthalmic manifestations of sarcoidosis: clinical spectrum, evaluation, and management. J Neuroophthalmol 2001; 21:132-137.
3. Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol 2000; 84:110-116.
4. Turner RG, Geraint J, Friedmann AI, Vijendram M. Neuro-opthalmic sarcoidosis. Br J Ophthalmol 1975; 59:657-663.
5. Diestelmeier MR, Sausker WF, Pierson DL, Rodman OG. Sarcoidosis manifesting as eyelid swelling. Arch Dermatol 1982; 118:356-357.
6. Stern BJ, Krumholz A, Johns C, et al. Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42:909-917.
7. Heuser K, Kerty E. Neuro-ophthalmological findings in sarcoidosis. Acta Ophthalmol Scand 2004; 82:723-729.
8. Allen RK, Sellars RE, Sandstrom PA. Sarcoidosis A prospective study of 32 patients with neurosarcoidosis. Vasc Diffuse Lung Dis 2003; 20:118-125.
9. Ng D, Jacobs M, Mantil J. Combined C-11 methionine and F-18 FDG PET imaging in a case of neurosarcoidosis. Clin Nucl Med 2006; 31:373-375.
10. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Statement on sarcoidosis. Am J Respir Crit Care Med 1999; 160:736-755.
11. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357:2153-2165.
12. Iwai K, Tachibana T, Takemura T, et al. Pathological studies on sarcoidosis autopsy. I: Epidemiological features of 320 cases in Japan. Acta Pathol Jpn 1993; 43 (7-8):372-376.
13. Terushkin V, Stern BJJudson MA, et al. Neurosarcoidosis: presentations and management. Neurologist 2010; 16:2-15.
14. Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145:234-241.
15. Lamirel C, Badelon I, Gout O, et al. Neuro-ophthalmologic initial presentation of sarcoidosis. J Fr Ophtalmol 2006; 29:241-249.
16. Koczman JJ, Rouleau J, Gaunt M, et al. Neuro-ophthalmic sarcoidosis: the University of Iowa experience. Semin Ophthalmol 2008; 23:157-168.
17. Robinson BW, McLemore TL, Crystal RG. Interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985; 75:1488-1495.
18. Zissel G, Prasse A, Müller-Quernheim J. Sarcoidosis- immunopathogenetic concepts. Semin Respir Crit Care Med 2007; 28:3-14.
19. Terao I, Hashimoto S, Horie T. Effect of GM-CSF on TNF-alphaand IL-1-beta production by alveolar macrophages and peripheral blood monocytes from patients with sarcoidosis. Int Arch Allergy Immunol 1993; 102:242-248.
20. Gudmundsson G, Hunninghake GW. Interferon-γ is necessary for the expression of hypersensitivity pneumonitis. J Clin Invest 1997; 99:2386-2390. (Pubitemid 27227715)
21. Homolka J, Muller-Quernheim J. Increased interleukin 6 production by bronchoalveolar lavage cells in patients with active sarcoidosis. Lung 1993; 171:173-183.
22. Grunewald J, Eklund A. Role of CD4+ T cells in sarcoidosis. Proc AmThorac Soc 2007; 4:461-464.
23. *0301 patients with pulmonary sarcoidosis. Eur Respir J 2006; 27:451-459.
24. Muller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 1998; 12:716-738.
25. Wahlstrom J, Katchar K, Wigzell H, et al. Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis. Am J Respir Crit Care Med 2001; 163:115-121.
26. Zissel G, Homolka J, Schlaak J, et al. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med 1996; 54:713-719.
27. Ho LP, Urban BC, Thickett DR, et al. Deficiency of a subset of T-cells with immunoregulatory properties in sarcoidosis. Lancet 2005;365:1062-1072.
28. Kobayashi S, Kaneko Y, Seino K, et al. Impaired IFN-g production of V24 NKT cells in nonremitting sarcoidosis. Int Immunol 2004; 16:215-222.
29. Bresnitz EA, Strom BL. Epidemiology of sarcoidosis. Epidemiol Rev 1983; 5:124-156.
30. Kucera GP, Rybicki BA, Kirkey KL, et al. Occupational risk factors for sarcoidosis in African-American siblings. Chest 2003; 123:1527-1535.
31. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004; 170:1324-1330.
32. Rybicki BA, Amend KL, Maliarik MJ, Iannuzzi MC. Photocopier exposure and risk of sarcoidosis in African -American sibs. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:49-55.
33. Gorham ED, Garland CF, Garland FC, et al. Trends and occupational associations in incidence of hospitalized pulmonary sarcoidosis and other lung diseases in Navy personnel: a 27-year historical prospective study, 1975-2001. Chest 2004; 126:1431-1438.
34. Barnard J, Rose C, Newman L, et al. Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS). J Occup Environ Med 2005; 47:226-234.
35. Prezant DJ, Dhala A, Goldstein A, et al. The incidence, prevalence, and severity of sarcoidosis in New York City firefighters. Chest 1999; 116:1183-1193.
36. Izbicki G, Chavko R, Banauch GI, et al. World Trade Center 'sarcoid-like' granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest 2007; 131:1414-1423.
37. Abe C, Iwai K, Mikami R, Hosoda Y. Frequent isolation of Propionibacterium acnes from sarcoidosis lymph nodes. Zentbl Bakteriol Mikrobiol Hyg A 1984; 256:541-547.
38. Eishi Y, Suga M, Ishige I, et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol 2002; 40:198-204.
39. Ichikawa H, Kataoka M, Hiramatsu J, et al. Quantitative analysis of propionibacterial DNA in bronchoalveolar lavage cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25:15-20.
40. *1101. J Clin Immunol 2010; 30:157-166.
41. Carlisle J, Evans W, Hajizadeh R, et al. Multiple Mycobacterium antigens induce interferon-gamma production from sarcoidosis peripheral blood mononuclear cells. Clin Exp Immunol 2007; 150:460-468.
42. Drake WP, Dhason M, Nadaf BE, et al. Cellular recognition of Mycobacterium tuberculosis ESAT-6 and katG peptides in systemic sarcoidosis. Infect Immun 2007; 75:527-530.
43. Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005; 201:755-767.
44. Chen ES, Wahlstrom J, Song Z, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. Immunology 2008; 181:8784-8796.
45. Dubaniewicz A, Trzonkowski P, Dubaniewicz-Wybieralska M, et al. Mycobacterial heat shock protein-induced blood T lymphocytes subsets and cytokine pattern: comparison of sarcoidosis with tuberculosis and healthy controls. Respirology 2007; 12:346-354.
46. Dubaniewicz A. Mycobacterium tuberculosis heat shock proteins and autoimmunity in sarcoidosis. Autoimmun Rev 2010; 9:419-424.
47. Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med 2010; 181:360-373.
48. Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis: A Case-Control Etiologic Study of Sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001; 164:2085-2091.
49. Hedfors E, Möller E. HL-A antigens in sarcoidosis. Tissue Antigens 1973; 3:95-98.
50. Brewerton DA, Cockburn C, James DC, et al. HLA antigens in sarcoidosis. Clin Exp Immunol 1977; 27:227-229.
51. *1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003; 73:720-735.
52. Iannuzzi MC, Maliarik MJ, Poisson LM, Rybicki BA. Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African-Americans. Am J Respir Crit Care Med 2003; 167:1225-1231.
53. Rybicki BA, Iannuzzi MC. Sarcoidosis and human leukocyte antigen class I and II genes: it takes two to tango? Am J Respir Crit Care Med 2004; 169:665-666.
54. Grunewald J, Eklund A, Olerup O. Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med 2004; 169:696-702.
55. *0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 2002; 27:406-412.
56. Walid MS, Ajjan M, Grigorian AA. Neurosarcoidosis: the great mimicker. J Natl Med Assoc 2008; 100:859-861.
57. Delaney P. Neurologic manifestations in sarcoidosis: review of the literature, with a report of 23 cases. Ann Intern Med 1977; 87:336-345. (Pubitemid 8177365)
58. Scott TS, Brillman J, Gross JA. Sarcoidosis of the peripheral nervous system. Neurol Res 1993; 15:389-390.
59. Gullapalli D, Phillips LH 2nd. Neurologic manifestations of sarcoidosis. Neurol Clin 2002; 20:59-83.
60. Hoitsma E, Sharma OP. Neurosarcoidosis. Eur Respir Mon 2005; 32:164-187.
61. Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol 2001; 248:363-372.
62. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis: diagnosis and management. Q J Med 1999; 92:103-117.
63. Lower EE, Weiss KL. Neurosarcoidosis. Clin Chest Med 2008; 29:475-492.
64. Frohman LP, Guirgis M, Turbin RE, Bielory L. Sarcoidosis of the anterior visual pathway: 24 new cases. J Neuroophthalmol 2003; 23:190-197.
65. Beardsley TL, Brown SV, Sydnor CF, et al. Eleven cases of sarcoidosis of the optic nerve. Am J Ophthalmol 1984; 97:62-77.
66. Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol 1986; 102:297-301.
67. Kawaguchi T, Hanada A, Horie S, et al. Evaluation of characteristic ocular sign and systemic investigation in ocular sarcoidosis patients. Jpn J Ophthalmol 2007; 51:121-126.
68. Hosoya S, Kataoka M, Nakata Y, et al. Clinical features of 125 patients with sarcoidosis: Okayama University Hospital review of a recent 10-year period. Acta Med Okayama 1992; 46:31-36.
69. Prior C, Barbee RA, Evans PM, et al. Lavage versus serum measurements of lysozyme, angiotensin converting enzyme and other inflammatory markers in pulmonary sarcoidosis. Eur Respir J 1990; 3:1146-1154.
70. Kruit A, Grutters JC, Gerritsen WB, et al. ACE I/D-corrected Z-scores to identify normal and elevated ACE activity in sarcoidosis. Respir Med 2007; 101:510-515.
71. Tomita H, Sato S, Matsuda R, et al. Serum lysozyme levels and clinical features of sarcoidosis. Lung 1999; 177:161-167.
72. Turton CW, Grundy E, Firth G, et al. Value of measuring serum angiotensin I converting enzyme and serum lysozyme in the management of sarcoidosis. Thorax 1979; 34:57-62.
73. Aerts JM, Hollak CE, van Breemen M, et al. Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr Suppl 2005; 94:43-46.
74. Grosso S, Margollicci MA, Bargagli E, et al. Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. Scand J Clin Lab Invest 2004; 64:57-62.
75. Bargagli E, Maggiorelli C, Rottoli P. Human chitotriosidase: a potential new marker of sarcoidosis severity. Respiration 2008; 76:234-238.
76. Boot RG, Hollak CE, Verhoek M, et al. Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. Clin Chim Acta 2010; 411:31-36.
77. Drent M, Mansour K, Linssen C. Bronchoalveolar lavage in sarcoidosis. Semin Respir Crit Care Med 2007; 28:486-495.
78. Specks U, Martin WJ II, Rohrbach MS. Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. Am Rev Respir Dis 1990; 141:117-123.
79. Winterbauer RH, Lammert J, Selland M, et al. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 1993; 104:352-361.
80. Kantrow SP, Meyer KC, Kidd P, Raghu G. The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis. Eur Respir J 1997; 10:2699-2700.
81. Shigemura M, Nasuhara Y, Konno S, et al. Levels of transferrin in bronch-oalveolar lavage fluid in sarcoidosis. Lung 2010; 188:151-157.
82. Matsuo T, Itami M, Shiraga F. Choroidopathy in patients with sarcoidosis observed by simultaneous indocyanine green and fluorescein angiography. Retina 2000; 20:16-21.
83. Atmaca LS, Atmaca-Sönmez P, Idil A, et al. Ocular involvement in sarcoidosis. Ocul Immunol Inflamm 2009; 17:91-94.
84. Streletz LJ, Chambers RA, Bae SH, Israel HL. Visual evoked potentials in sarcoidosis. Neurology 1981; 31:1545-1549.
85. Gott PS, Kumar V, Kadakia J, Sharma OP. Significance of multimodality evoked potential abnormalities in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:159-164.
86. Oksanen V, Salmi T. Visual and auditory evoked potentials in the early diagnosis and follow-up of neurosarcoidosis. Acta Neurol Scand 1986; 74:38-42.
87. Kvanta A, Seregard S, Kopp ED, et al. Choroidal biopsies for intraocular tumors of indeterminate origin. Am J Ophthalmol 2005; 140:1002-1006.
88. Bechrakis NE, Foerster MH, Bornfeld N. Biopsy in indeterminate intraocular tumors. Ophthalmology 2002; 109:235-242.
89. Mahac J, Lu P, Iannuzzi M, et al. Total body FDG PET scans in sarcoidosis. Chest 2006; 130:127S.
90. Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35:1537-1543.
91. Walker A, Tyor W. Neurosarcoidosis. Curr Treat Options Neurol 2001; 3:529-535.
92. Vourlekis JS, Sawyer RT, Newman LS. Sarcoidosis: developments in etiology, immunology, and therapeutics. Adv Intern Med 2000; 45:209-257.
93. Reed L, Abbas S, Fletcher J. Neurosarcoidosis responding to steroids. Am J Roentgenol 1986; 146:819-821.
94. Bruns F, Pruemer B, Haverkamp U, Fischedick AR. Neurosarcoidosis: an unusual indication for radiotherapy. Br J Radiol 2004; 77:777-779.
95. Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995; 52:875-879.
96. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155:846-851.
97. Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157:1864-1868.
98. Chaussenot A, Bourg V, Chanalet S, et al. Neurosarcoidosis treated with mycophenolate mofetil: two cases. Rev Neurol 2007; 163:471-475.
99. Bhat P, Cervantes-Castañeda RA, Doctor PP, et al. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm 2009; 17:185-190.
100. Hammond ER, Kaplin AI, Kerr DA. Thalidomide for acute treatment of neurosarcoidosis. Spinal Cord 2007; 45:802-803.
101. Hoyle JC, Newton HB, Katz S. Prognosis of refractory neurosarcoidosis altered by thalidomide: a case report. J Med Case Rep 2008; 2:27.
102. Katz JM, Bruno MK, Winterkorn JM, Nealon N. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch Neurol 2003; 60:426-430.
103. Salama B, Gicquel JJ, Lenoble P, Dighiero PL. Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can J Ophthalmol 2006; 41:766-768.